A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

Key Inclusion Criteria:

• Patients must be at least 18 years of age at the time of signing the informedconsent.

• Patients must be willing and able to provide written informed consent

• Patients must have locally advanced or metastatic solid tumors that have progressedafter standard of care therapy or for which no standard therapy exists

• Tumors must harbor a TP53 R175H variant mutation confirmed by an accreditedlaboratory-based test

• Patients must be HLA-A*02:01 positive by central assay

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at the timeof enrollment

• Adequate hematological, renal and hepatic function

• Per Investigator judgement, patient is willing and able to complete study visitsand/or procedures per the protocol and comply with study requirements for studyparticipation

Key Exclusion Criteria:

• Patients with Li-Fraumeni syndrome or other known germline p53 R175H mutation

• Patients who have received other p53 R175H-directed therapies

• Patients who have not fully recovered from adverse events due to previous anticancertherapies

• Patients with active infection requiring systemic antimicrobial therapy

• Any other primary malignancy within the 2 years prior to enrollment (except for non-melanoma skin cancer, carcinoma in situ (eg, cervix, bladder, breast) or prostatecancer in remission.

• Known active central nervous system metastases and/or carcinomatous meningitis